The fact that gastrointestinal stromal tumor (GIST) is a rare tumor type, with an estimated incidence of 3,300 to 6,000 new cases per year in the United States, can make it more challenging for oncologists and other members of the cancer care team to stay up to date on the latest therapeutic developments. Treatment for GIST has seen exciting progress this year, with two new FDA approvals for metastatic disease. This episode of Oncology Data Advisor features Dr. Shreyaskumar Patel, Robert R. Herring Distinguished Professor of Cancer Research and Center Medical Director of the Sarcoma Center at the University of Texas MD Anderson Cancer Center in Houston, Texas, in a discussion that covers the changing treatment landscape, adverse events of concern with novel therapies, and advice for members of the cancer care team as they seek to optimize outcomes for patients with GIST.

Discussion Notes

• On the challenges of treating patients with GIST (00:56)

• On how the approvals of avapritinib and ripretinib have changed the

treatment landscape for metastatic disease (03:55)

• On managing adverse events of GIST therapies, including ripretinib and

avapritinib (09:17)

• On optimizing patient outcomes in GIST (14:10)

• Summary of key points crucial to caring for patients with GIST (15:33)